Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYoshio YoshidaMOMakoto OrisakaDIDaisuke Inoue

Discussion

Loading...

Member takes

Overview

Review explores immune checkpoint inhibitors safety and effectiveness in older adults, suggesting age should not limit treatment considerations.

Key Points

  • ICIs show significant survival benefits in older cancer patients, indicating potential equal efficacy to younger cohorts.
  • Clinical evidence emphasizes the importance of individualized treatment plans based on biological age rather than solely chronological age.
  • Immunosenescence and the tumor microenvironment play crucial roles in ICI responses, influencing treatment outcomes in older adults.
  • Management of immune-related adverse events is critical, as their incidence may not be higher in older patients despite comorbidities.

Cite This Study

Yoshida et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f2995https://doi.org/10.1080/14656566.2025.2548887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients2024 · 1 citations
  2. 2Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients2024 · 35 citations
  3. 3Cancer Characteristics and Immunotherapy in Older Adults: Treatment Approaches, Immune-Related Adverse Events, and Management Considerations2026 · 1 citations
  4. 4Impact of age on immune-related toxicities and survival in non–small cell lung cancer treated with immune checkpoint inhibitors: A multicenter retrospective study.2026
  5. 5Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma2026